Predicting risk of cardiovascular disease and the cost-effectiveness of interventions in Thailand Stephen Lim On Behalf of the Setting Priorities using.

Slides:



Advertisements
Similar presentations
WHO CVD Atlas WHO Stroke Atlas The Burden of CVD in Asia: Stroke Deaths by Country,
Advertisements

Project Partners: 計劃夥伴: Funded by: 捐助機構: Gap of Health Care for Midlife Women: Controlling Risk Factors of Stroke as Example Chau Pui Hing CADENZA Project,
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Mortality benefit from reduction in sodium consumption 1 Hypertension affects one-third of the US population, of which less than half have their blood.
K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.
CVD risk estimation and prevention: An overview of SIGN 97.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Main Trial Design and Trial Status
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
COHORH STUDY A research paper on BMJ. What is cohort study? Investigates from exposure to outcome, in a group of patients without, or with appropriate.
Journal Club Alcohol and Health: Current Evidence July–August 2004.
Cohort Studies.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2010.
Morbidity & Mortality: 2012 Chart Book on Cardiovascular, Lung, and
Body Weight and Mortality: New Population Based Evidences Body Weight and Mortality: New Population Based Evidences Dongfeng Gu, MD Dongfeng Gu, MD Fu.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
LIFESTYLE MODIFICATIONS FOR PREVENTING HEART DISEASE [e.g. HEART ATTACKS] [ primary prevention of coronary artery disease ] DR S. SAHAI MD [Med.], DM [Card]
Tt HRB Centre for Health and Diet Research The burden of hypertension Ivan J Perry, Dept. of Epidemiology and Public Health, University College Cork. Institute.
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.
HSTAT1101: 27. oktober 2004 Odd Aalen
Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.
CVD preventive interventions WORKSHOP Jurate Klumbiene Kaunas University of Medicine, Kaunas, Lithuania.
1 Population Health Model (POHEM) AMI Acknowledgements: CCORT for collaboration and funding.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
The effects of initial and subsequent adiposity status on diabetes mellitus Speaker: Qingtao Meng. MD West China hospital, Chendu, China.
Epidemiology of CVD in the Elderly Karen P. Alexander MD Duke University Medical Center Duke Clinical Research Institute Disclosures: (1) Minor Research:
Lecture 17 (Oct 28,2004)1 Lecture 17: Prevention of bias in RCTs Statistical/analytic issues in RCTs –Measures of effect –Precision/hypothesis testing.
10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.
ASSIGN Paul Ryan, Clinical Director, North Glasgow CHCP.
10 Points to Remember on the Assessment of Cardiovascular RiskAssessment of Cardiovascular Risk Summary Prepared by Melvyn Rubenfire, MD.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Studying mortality trends: The IMPACT CHD Policy Model
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Case-control study Chihaya Koriyama August 17 (Lecture 1)
Predictive Value of Coronary Calcium Scoring Matthew Budoff, MD, FACC, FAHA Associate Professor of Medicine UCLA School of Medicine Director, Cardiac CT.
LEADING RESEARCH… MEASURES THAT COUNT Challenges of Studying Cardiovascular Outcomes in ADHD Elizabeth B. Andrews, MPH, PhD, VP, Pharmacoepidemiology and.
1 Lecture 6: Descriptive follow-up studies Natural history of disease and prognosis Survival analysis: Kaplan-Meier survival curves Cox proportional hazards.
Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
Section III. Assessment of Overall Cardiovascular Risk in Hypertensive Patients 2015 Canadian Hypertension Education Program Recommendations.
1 Multivariable Modeling. 2 nAdjustment by statistical model for the relationships of predictors to the outcome. nRepresents the frequency or magnitude.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
4S: Scandinavian Simvastatin Survival Study
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Health impact and monetary costs of dietary salt reduction policies: the CHD Policy Model Andrew Moran MD, MPH Department of Medicine, Columbia University.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.
Objectives of Training To provide you with an overview of MSD Informatics Software. To provide you with sufficient training to be able to use MSD Informatics.
Kelsey Vonderheide, PA1.  Heart Failure—a large number of conditions affecting the structure and function of the heart that make it difficult for the.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Case 1: Elevated LDL-C in a Young Adult. Page 2 of 10 *DALY; disability-adjusted life years Routine checkup:  Age:33 years  Sex: male  Status: Except.
○ South Asians (SAs) have high rates of CHD which are not entirely explained by traditional CVD risk factors. ○ The association of a family history of.
Nephrology Journal Club The SPRINT Trial Parker Gregg
Alcohol, Other Drugs, and Health: Current Evidence July–August 2017
Alina M. Allen MD, Patrick S. Kamath MD, Joseph J. Larson,
Copyright © 2007 American Medical Association. All rights reserved.
Population Health Model (POHEM)
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Systolic Blood Pressure Intervention Trial (SPRINT)
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Determinants of new onset diabetes among hypertensive patients randomised in the ASCOT-BPLA Trial Dr Ajay K Gupta International Centre for Circulatory.
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Kanguk Samsung Hospital, Sungkyunkwan University
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Baseline Characteristics of the Subjects*
Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.
Presentation transcript:

Predicting risk of cardiovascular disease and the cost-effectiveness of interventions in Thailand Stephen Lim On Behalf of the Setting Priorities using Information on Cost-Effectiveness (SPICE) Project

Top Ten Causes of Disability Adjusted Life Year (DALYs) by Sex, Thailand 1999

Thai Burden of risk factors, 1999

Prevention of CVD 2 different but complementary approaches to prevention: 1. Population-wide approach – aims to reduce levels of risk factor(s) across the whole population 2. High risk approach – targets prevention towards those who are at higher risk, e.g. high blood pressure, high cholesterol

Targeting high-risk How do we target those at high risk?  Traditionally, by thresholds of individual risk factors, e.g. systolic blood pressure ≥ 140mmHg (hypertension)  More recent approach uses absolute risk of CVD in, e.g. next 10 years  E.g. using risk prediction equations from the Framingham study

Absolute risk Absolute risk of CVD takes into account 1. Multiple risk factors determine CVD risk  age, sex, blood pressure, cholesterol, smoking, diabetes, etc

Absolute risk Absolute risk of CVD takes into account 1. Multiple risk factors determine CVD risk  age, sex, blood pressure, cholesterol, smoking, diabetes, etc 2. Continuous measurements of risk factors  e.g. relationship between blood pressure and CVD is not dichotomous (i.e. having hypertension or not having hypertension) but is continuous

Source: World Health Report 2002

Absolute risk Absolute risk of CVD takes into account 1. Multiple risk factors determine CVD risk  age, sex, blood pressure, cholesterol, smoking, diabetes, etc 2. Continuous measurements of risk factors  e.g. relationship between blood pressure and CVD is not dichotomous (i.e. having hypertension or not having hypertension) but is continuous  An individual with moderately elevated levels of multiple risk factors may be at higher risk than an individual with high levels of a single risk factor

Risk prediction equations Determination of absolute risk is based on cohort studies examining the relationship between risk factors and CVD outcomes  Uses survival analysis (Cox regression or Weibull models) to determine predictive risk equation Many of the risk equations in use are based on the Framingham study  These have been validated and “adjusted” for use in other cohorts and settings, e.g. China, Australia, Europe, New Zealand

Risk prediction equations The Electricity Generating Authority of Thailand (EGAT) cohort study provides important information on the relationship between risk factors and CVD outcomes in a Thai population  3,499 employees of EGAT (2,702 males, 797 females) aged years  Physical examinations (including blood) 1985, 1997, 2002  Information on a range of fatal and non-fatal CVD events  2 nd cohort of individuals followed from 1997

Risk prediction equations EGAT:  Developed a range of risk prediction equations Coronary Heart Disease (CHD), Diabetes Equations used to develop a point score system for predicting absolute risk  Validation of other risk prediction equations from the Framingham study and China cohorts Show, like other studies, that Framingham equations predict relative risk well, but overestimate absolute risk

EGAT-SPICE collaboration Use EGAT equations to determine predicted CHD risk for individuals in the National Health Examination Survey 3

Cox proportional hazards model from EGAT 2418 subjects, 74 CHD events Developed by Dr Sukit

Apply EGAT score to NHES 3 Using raw data from NHES  No sample weights  Not yet cleaned Apply to males aged only  Excluding HDL as this is not measured  Some inconsistencies between EGAT and NHES risk factors definitions NHES: Alcohol in last 12 months EGAT: Current alcohol use

Apply EGAT score to NHES 3 Cox-proportional harzards model was used to determine individual risk Risk estimate = 1 – S 0 (t) exp(∑βX- ∑βX) where,S 0 (t) is the average survival time at time t β’s are the Cox-regression coefficients X are the individual RF values X are the mean RF values

Apply EGAT score to NHES 3 For male aged 55, SBP 160, Chol 250mg/dl, diabetic, smoker, waist 102cm, no alcohol  ∑βX = age* sbp* Tch* diabetes* smoke* alcohol* waist90*  ∑βX = 55* * * * * * * =  S 0 (10) from Kaplan-Meier estimate from EGAT is  ∑βX is Risk estimate = 1 – exp( ) = % risk of CHD event over the next 10 years

Preliminary analysis – Please do not quote

Overall predicted 10-year CHD risk Predicted risk of CHD lower in NHES 3 (0.62% compared with 1.09% from EGAT) Preliminary analysis – Please do not quote

Comparison of mean RF values Preliminary analysis – Please do not quote

Ongoing work Repeated measures analysis Currently using only 1985 examination with 17 year follow-up Repeated measures allows us to use 1997, 2002 examination also Causal web estimation using hierarchical models

Causal web

Risk prediction equations Limitations Males aged not sufficient numbers to generate risk equation for women Time period is  Risk of CVD in this period may be quite different from risk of CVD today Alternative approach is to calibrate Framingham risk prediction equations for use in Thailand

Calibration of absolute risk Population estimates of disease incidence, e.g. from Thai BOD Framingham Risk prediction + Absolute risk specific to the population Adjusted for local risk factor prevalence and underlying risk + Risk factor prevalence data e.g. from NHES3

Example Framingham 1-year CHD risk for this individual is Framingham 1-year CHD risk for NHES females aged 55 is Female, 55 years, total cholesterol 6.7, no diabetes, current smoker, SBP 140mmHg = 4.70 Risk for this individual relative to all Thai females aged 55: Population-level incidence of CHD for females aged 55 is Individual calibrated CHD risk is 4.7 * = In other words, this individual has a 2.4% chance of having a CHD event in the next year RR =

Risk prediction Approach adjusts for:  Risk factor prevalence (NHES)  Underlying risk of CVD (population-level incidence of CVD from Thai BOD) Underlying assumption is that relative risk of risk factors is the same across the two populations  Supported by EGAT data for males

Issues for CVD prevention Many different strategies exist for reducing the risk of CVD How can we target high-risk individuals?  Traditional approach using thresholds of individual risk factors, e.g. systolic blood pressure ≥ 140mmHg  Absolute risk approach takes into account multiple risk factors e.g. age, sex, blood pressure, cholesterol, smoking, diabetes Should a cholesterol test be included to identify high- risk individuals?

Issues for CVD prevention Due to these difficulties, it is likely that the large amount of resources that are devoted to preventive strategies for CVD are not being used in an optimal manner. Cost-effectiveness analysis can tell us which interventions are optimal given currently available resources  Which mix of strategies is most efficient in reducing the burden of CVD?

Modelling cost-effectiveness Rely on state transition (“Markov”) models  Portions of a cohort move through different mutually exclusive states over time  Movement between states is determine by transition probabilities Model the current Thai population in terms of CVD outcomes over time

Modelling cost-effectiveness Year 1 Year 2 Year 0 ALIVECHD DEAD

Modelling cost-effectiveness Transition probabilities for CVD can be determined in a similar way to calibration of CVD absolute risk equations Allows us to simulate individuals with different risk factor profiles / absolute risk through the state transition model

Modelling cost-effectiveness Repeat process under “no intervention” and “intervention” scenarios  e.g. statins may reduce the transition between ALIVE and CHD by 30% Can then determine  health years gained by the intervention  cost of interventions  potential cost savings due to reduced cases of CVD  Cost-effectiveness

Natural history of CVD Model structure depends on natural history of the disease being modelled 2 major types of CVD events  Acute coronary syndromes (ACS), including myocardial infarction and unstable angina pectoris Major sequelae are angina and heart failure  Stroke including both hemorrhagic and ischemic sub- types Multiple risk factors for both ACS and stroke  Age, sex, blood pressure, cholesterol, diabetes, etc

Natural history of CVD Prognosis of both ACS and Stroke are similar  (very) high case-fatality in first 28-days  risk of mortality in 28-days survivors remains elevated thereafter Need to differentiate between initial mortality (first 28-days or first year) and risk of mortality thereafter

T7 T5 T3 T1 T4 CVD model structure

Data sources EGAT  Incidence:mortality ratios  Some information on case-fatality rates  Risk prediction equation Vital registration with cause of death corrections  Mortality from CVD National Health Examination Survey  Self-reported prevalence of CHD and stroke  Risk factor prevalence ACS and Stroke registries  In-hospital case fatality Major limitation is lack of information on out-of- hospital case-fatality

Results from analysis in Australia

Reasons for inefficiency of current practice in Australia Absolute risk vs Risk factor thresholds Not enough attention to lifestyle and public health interventions  Community programs  Dietary counselling  Phytosterol supplementation Current resources directed at less efficient classes of BP lowering drugs  e.g. ACE inhibitors

Summary There is potential to increase the efficiency of CVD prevention efforts with :  The development of robust tools to predict absolute risk of CVD in clinical practice  Estimates of the cost-effectiveness of different prevention strategies